Identifying biomarkers for radiation pneumonitis in lung cancer patients
A Multicenter Prospective Observational Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis
This study is trying to find markers in the blood and other data that can help predict radiation pneumonitis in lung cancer patients receiving radiation therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Huazhong University of Science and Technology Academic / other |
| Drugs / interventions | Radiation |
| Locations | 3 sites (Wuhan, Hubei and 2 other locations) |
| Trial ID | NCT05448703 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify biomarkers related to radiation pneumonitis in lung cancer patients undergoing thoracic radiotherapy. It involves collecting clinical data, CT images, and blood samples from patients treated at multiple hospitals. The study will follow patients during and after treatment to evaluate the relationship between radiation pneumonitis and other treatment-related toxicities. Additionally, it seeks to construct a predictive model for radiation pneumonitis using machine learning techniques and assess the impact on patient survival and treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates include lung cancer patients aged over 18 who are receiving thoracic radiotherapy with a minimum radiation dose of 45 Gy.
Not a fit: Patients with severe cardiopulmonary diseases or those who have previously undergone thoracic irradiation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prediction and management of radiation pneumonitis, enhancing the quality of life and treatment outcomes for lung cancer patients.
How similar studies have performed: While studies on radiation pneumonitis exist, this approach of integrating biomarkers and predictive modeling is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Clinical diagnosis of lung cancer by histology 2. Radiation dose at least 45 Gy 3. Karnofsky \>60 4. Age\>18 5. Life expectancy of at least 6 months Exclusion Criteria: 1. Previous thoracic irradiation 2. Severe cardiopulmonary diseases
Where this trial is running
Wuhan, Hubei and 2 other locations
- Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
- Jingjiang People' Hospital — Jingjiang, Jiangsu, China (Recruiting)
Study contacts
- Principal investigator: Xianglin Yuan, PhD — Tongji Hospital
- Study coordinator: Xianglin Yuan, PhD
- Email: yuanxianglin@hust.edu.cn
- Phone: +8613667241722
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.